Blog

Celgene Acquires Impact Biomedicines, Adding Myeloproliferative Neoplasm Drug Fedratinib to Its Pipeline

Celgene Corporation (NASDAQ:CELG) and Impact Biomedicines today announced the signing of a definitive agreement in which Celgene will acquire Impact Biomedicines, which is developing fedratinib for myelofibrosis and polycythemia vera. Under the terms of the agreement, Celgene will pay approximately $1.1 billion upfront and up to $1.25 billion in contingent payments based on regulatory approval […]

Dr-Mascarenhas-presenting-on-Nutlin-at-ASH-2017

ASH 2017 Nutlin Antagonist Shows Activity in Polycythemia Vera

The investigational Nutlin family antagonist idasanutlin demonstrated significant activity and was well tolerated after multiple cycles of exposure in patients with refractory polycythemia vera (PV). Data from a 2-part single-institution, open-label, dose-escalation phase I study showed a 75% overall response rate when idasanutlin was given as a monotherapy or in combination with pegylated interferon, said […]

What is an MPN Specialist?

A Few Simple Criteria If your doctor has never been to the ASH (American Society of Hematology) conference, the largest hematology convention in the world, and never published a peer-reviewed research paper, he or she isn’t likely to be an MPN specialist. Also, if their bio lists 12+ clinical interests, their focus is NOT likely […]

Minimal Residual Disease or Cure in MPNs? Rationales and perspectives on Combo Therapy with Interferon-alpha2 and Ruxolitinib

This abstract is provided by Mads Emil Bjorn & Hans Carl Hasselbalch – Department of Hematology, Region Zealand, Roskilde, Denmark Abstract Introduction: The therapeutic landscape of the Philadelphia-negative myeloproliferative neoplasms (MPNs) is markedly changing consequent to the development of JAK-inhibitors and the use of ruxolitinib (RUX) in patients with myelofibrosis (MF) and patients with polycythemia […]

Dr Ruben Mesa, MPN Specialist named new director of University Texas Health Care Cancer Center in San Antonio

2023 Update – Dr. Ruben Mesa named to Lead Atrium Health Cancer Program Publisher’s Note (David Wallace) As a Charlotte native, I’m really excited to witness the tremendous growth of our world-class cancer centers along with the groundbreaking of Charlotte’s first 4-year medical school. The school is part of the Pearl CLT innovation district. The […]

A New Therapeutic Target for Myelofibrosis is cause for Gli

Abstract Myeloproliferative neoplasm cells recruit Gli1 positive mesenchymal stromal cells to transdifferentiate into fibrosis-causing myofibroblasts, a process that can be inhibited by a Gli inhibitor. Bone marrow fibrosis (BMF), characterized by deposition of reticulin and collagen fibers in the marrow, is a hallmark of primary myelofibrosis (PMF) and other myeloproliferative neoplasms (MPNs). PMF is characterized […]

Understanding Polycythemia Vera

Understanding Polycythemia Vera (PV), A Rare Blood Cancer Behind the Mystery, Polycythemia Vera Every year, millions of patients, families and caregivers are impacted by cancer in the United States. Some cancers are well-known, but others are quite rare. Polycythemia Vera (PV) is part of a group of rare blood cancers called Myeloproliferative Neoplasms (MPNs). PV […]

RuxoPeg_clinical_trial_for_MF_patients_in_Europe-1024x629

Dr Mesa and Dr Mikhael Discuss Latest MPN Research 2017

A Solid Summary on the Latest MPN Research in 2017 Drs. Joseph R. Mikhael and Ruben A. Mesa analyze and discuss pertinent clinical studies and late breaking updates pertaining to the care of patients with chronic myelogenous leukemia (CML) and myeloproliferative neoplasms (MPN) in this Best of the Day discussion from the annual hematology meeting […]

Dying for Answers – Radiation Link to Myeloproliferative Neoplasms

Long Term Exposure to Radiation puts you at higher risk for MPN The Savannah River Site is on a list of qualified places for Special Exposure Cohort Employees (SEC) The SEC allows eligible claimants to be compensated without the completion of a NIOSH radiation dose reconstruction or determination of the probability of causation. To qualify […]

Survey Seeking Essential Thrombocythemia Patients to Share Their Experiences

A survey is being conducted to learn more about the most common symptoms experienced by ET patients, and how these symptoms affect the lives of patients. This information may help improve how the patient’s experience is accounted for in clinical trials that measure the effect of treatments. The study is being conducted by Quintiles IMS […]